Stockreport

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country [Yahoo! Finance]

Karyopharm Therapeutics Inc.  (KPTI) 
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.karyopharm.com/investor-relations
PDF lines of systematic therapy has been included in the 2024 China National Reimbursement Drug List (NRDL), which will officially take effect on January 1, 2025. (Source: A [Read more]